Bannerbild German Brest Group

JCO top-cited

22.01.2018

Our Paper about PIK3CA-Mutations is one of the most-cited papers in JCO.

Our paper about PIK3CA-Mutations from 2014 with 107 citations is one of the most-cited Paper in Journal of Clinical Oncology. We are very proud about this confirmation of the relevance of your research.

"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer."
J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.

News

  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

    Mehr ...
  • 04.02.2019 ESMO Breast Cancer 2019

    ESMO Breast Cancer 2019

    ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.

    Mehr ...
  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl among highly cited researchers 2018

    Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.

    Mehr ...
  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd